---
title: "OKYO Pharma files Form 3 for Chief Scientific Officer Rajkumar V. Patil"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294257626.md"
description: "OKYO Pharma filed Form 3 with the SEC regarding Chief Scientific Officer Rajkumar V. Patil. The filing discloses the reporting of 16,667 common shares and stock options covering 527,032 shares, priced between $1.46 and $2.75."
datetime: "2026-07-29T20:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294257626.md)
  - [en](https://longbridge.com/en/news/294257626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294257626.md)
generator: "portal-rs"
---

# OKYO Pharma files Form 3 for Chief Scientific Officer Rajkumar V. Patil

-   OKYO Pharma Chief Scientific Officer Rajkumar V. Patil reported 16,667 common shares, with stock options covering 527,032 shares priced from $1.46 to $2.75. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035203), on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)

## Related News & Research

- [OKYO Pharma chairman raises stake to 20.51% after buying 25,000 shares at $ 1.4](https://longbridge.com/en/news/293329898.md)
- [OKYO Pharma joins BTIG Biotechnology Conference 2026](https://longbridge.com/en/news/293920619.md)
- [TAESA energizes Garabi 2 converter, adding about R$ 24.2 million to Saíra annual revenue entitlement](https://longbridge.com/en/news/296538089.md)
- [SYNACT: Positive Phase 2b results for resomelagon in RA drive Phase 3 plans and strategic financing](https://longbridge.com/en/news/296439044.md)
- [Tenedora de Acciones CM names Alejandro Becerra Sepulveda as non-board corporate secretary, replacing Raul Mora Ponce](https://longbridge.com/en/news/296426919.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**